Canadian Journal of Cardiology

Recurrent Type III Kounis Syndrome: Will Anti–Immunoglobulin E Drug Be Another Option?

Published:December 09, 2019DOI:


      Kounis syndrome was recognized as the concurrence of acute cardiovascular events with hypersensitivity reactions. We report a case of Kounis syndrome type III (coronary thrombosis) variant in a 48-year-old man who had experienced recurrent acute myocardial infarctions after scallion-induced hypersensitivity reactions. After appropriate antithrombotic, antihistamine, and reperfusion strategies, the patient was found to have elevated levels of immunoglobulin E and chronic urticaria. Upon administration of omalizumab, there was an improvement of chronic urticaria, a decrease in immunoglobulin E levels, and resolution of the ischemic attacks.


      Il est reconnu que le syndrome de Kounis est caractérisé par la survenue concomitante d’événements cardiovasculaires aigus et de réactions d’hypersensibilité. Nous rapportons un cas de syndrome de Kounis de type III (thrombose coronaire) chez un homme de 48 ans qui avait subi des infarctus aigus du myocarde récurrents après des réactions d’hypersensibilité induites par l’oignon vert. Après des stratégies de traitement antithrombotique, de traitement antihistaminique et de reperfusion, on s’est aperçu que le patient avait des concentrations élevées d’immunoglobuline E et une urticaire chronique. À l’administration d’omalizumab, on a noté une amélioration de l’urticaire chronique, une diminution des concentrations d’immunoglobuline E et la fin des accidents ischémiques.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Itoh T.
        • Nakajima Y.
        • Morino Y.
        • Kounis N.G.
        Kounis syndrome: new classification.
        Int J Cardiol. 2018; 256: 11
        • Kounis N.G.
        • Koniari I.
        • Roumeliotis A.
        • et al.
        Thrombotic responses to coronary stents, bioresorbable scaffolds and the Kounis hypersensitivity-associated acute thrombotic syndrome.
        J Thorac Dis. 2017; 9: 1155-1164
        • Georgiadou P.
        • Voudris V.
        Platelet activation and stent thrombosis.
        Hellenic J Cardiol. 2017; 58: 49-50
        • Nakajima Y.
        • Itoh T.
        • Morino Y.
        Metal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis.
        Catheter Cardiovasc Interv. 2016; 87: 137-142

      Linked Article

      • Humanized Monoclonal Antibodies Against IgE Antibodies as Therapy for IgE-Mediated Coronary Syndromes: Are We There Yet?
        Canadian Journal of CardiologyVol. 36Issue 6
        • Preview
          Immunoglobulin E (IgE) antibodies are synthesized and released by B lymphocytes as a result of a complex interplay between genes, cytokines, and environmental antigen exposure. IgE antibodies participate in atopic diseases and systemic anaphylaxis, constituting components of a protein network implicated in signalling response to antigens and allergens.1 IgEs are very short lived in plasma (∼ 1 day), but receptor-bound IgE can remain fixed to cells in tissues for weeks or months. Their biologic activity is mainly dependent on binding to specific fragment crystallisable region (FcR) receptors high-affinity FCεRI and FCγRI and low-affinity FCεRII and FCγRII situated on the surface, mainly of mast cells, but also of basophils, eosinophils, monocytes, and epithelial and dendritic cells.
        • Full-Text
        • PDF